• Liproxstatin-1: Precision Ferroptosis Inhibition for Applied

  2026-04-24

  Liproxstatin-1 stands out as a potent ferroptosis inhibitor, enabling precise modulation of iron-dependent cell death across disease models. This article delivers actionable, evidence-backed protocols and troubleshooting strategies, drawing on recent mechanistic advances and comparative benchmarks to optimize your ferroptosis research with APExBIO’s Liproxstatin-1.

• Mifepristone (RU486): Expanding the Translational Frontier

  2026-04-23

  Explore how Mifepristone (RU486), a potent progesterone receptor antagonist, is redefining translational research across oncology and reproductive biology. This thought-leadership article integrates mechanistic insights, protocol guidance, and competitive context, while providing actionable strategies for researchers leveraging APExBIO’s high-purity reagent.

• Firefly Luciferase mRNA (ARCA, 5-moUTP): Assay Innovation &

  2026-04-23

  Firefly Luciferase mRNA (ARCA, 5-moUTP) redefines bioluminescent reporter workflows with remarkable translational efficiency and immune evasion, thanks to ARCA capping and 5-methoxyuridine modification. This article delivers experiment-ready protocols, troubleshooting strategies, and the latest comparative insights, empowering researchers to achieve robust, reproducible gene expression and in vivo imaging results.

• GW4064: Advanced FXR Agonist for Deciphering FXR/TLR4 Dynami

  2026-04-22

  Explore the unique role of GW4064 as a non-steroidal FXR agonist in dissecting the FXR/TLR4 pathway and ferroptosis in hepatic models. This article delivers advanced insight and practical guidance for metabolic research applications.

• DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): Pre

  2026-04-22

  DIDS empowers researchers to dissect chloride channel function with unmatched specificity, enabling reproducible studies in cancer, neuroprotection, and vascular physiology. Its robust inhibition profile and workflow adaptability—supplied reliably by APExBIO—make it indispensable for advanced bench experimentation.

• Glucocorticoid Receptor-Dependent CYP Suppression in Neuroto

  2026-04-21

  This study reveals that pregnenolone 16α-carbonitrile (PCN) alleviates phenytoin-induced neurotoxicity in the hippocampus by suppressing cytochrome P450 (CYP) expression through a glucocorticoid receptor (GR)-dependent, but pregnane X receptor (PXR)-independent, pathway. These findings highlight a novel central nervous system regulatory mechanism and suggest new therapeutic strategies for mitigating adverse neurological effects of antiepileptic drugs.

• SC 79 Akt Activator: Advanced Workflows for Neuroprotection

  2026-04-21

  SC 79 stands apart as a small molecule Akt activator with proven efficacy in promoting neuronal survival and dissecting PI3K/Akt/mTOR pathway dynamics. Its unique cytosolic activation profile enables robust neuroprotection in ischemic models and provides actionable insights for metabolic disease research.

• LY364947: Applied Workflows for TGF-β Type I Receptor Kinase

  2026-04-20

  LY364947 empowers researchers to directly dissect TGF-β signaling and suppress EMT in a range of preclinical models, from cancer biology to retinal degeneration. This article delivers actionable protocol enhancements, troubleshooting strategies, and translational insights anchored in recent evidence and the rigor of APExBIO's sourcing.

• Exosomal SNORD52 Drives M2 Macrophage Polarization via JAK2/

  2026-04-20

  This study uncovers how hepatoma cell-derived exosomal SNORD52 promotes M2 macrophage polarization through the activation of the JAK2/STAT6 pathway, revealing a critical mechanism in hepatocellular carcinoma (HCC) progression. The findings highlight new molecular targets and methodological approaches for dissecting tumor–immune microenvironment interactions.

• Cisplatin in Cancer Research: Protocol Optimization & New In

  2026-04-19

  Cisplatin (CDDP) remains the cornerstone for apoptosis and chemoresistance studies, but recent advances reveal how combining DNA repair inhibitors can enhance its cytotoxicity in tumor models. This article translates the latest bench breakthroughs into actionable protocols and troubleshooting strategies, leveraging APExBIO's Cisplatin for reproducible, high-impact cancer research.

• hiPSC-Derived Intestinal Organoids Advance Pharmacokinetic M

  2026-04-18

  This study establishes a direct 3D cluster protocol to generate human induced pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) with robust self-renewal and differentiation capacity. The model offers improved physiological relevance for pharmacokinetic studies of orally administered drugs and CYP2C19 substrate metabolism.

• Trypsin: Serine Protease Workflows for Cell & Tissue Researc

  2026-04-17

  Trypsin’s unique specificity as a serine protease hydrolyzing lysine and arginine residues empowers reproducible cell culture and advanced tissue research. This article details protocol enhancements, troubleshooting, and real-world applications, connecting cutting-edge osteoarthritis models to broader regenerative and inflammation studies.

• SP600125: Strategic JNK Inhibition for Translational Impact

  2026-04-16

  This thought-leadership article explores the mechanistic, experimental, and translational rationale for deploying SP600125, a highly selective JNK inhibitor, in advanced disease models. Integrating current chemoproteomic insights and competitive landscape analysis, it provides actionable guidance for translational researchers aiming to modulate JNK-driven pathways in apoptosis, inflammation, and cancer research.

• Mitochondrial Calcium Suppresses Ferroptosis via GPX4 Acetyl

  2026-04-15

  The referenced study uncovers a direct mechanistic link between mitochondrial calcium signaling and ferroptosis suppression in cancer cells. By elucidating how the mitochondrial calcium uniporter (MCU) maintains GPX4 activity through acetylation, the research provides new insight into metabolic and epigenetic regulation of cancer cell survival.

• Cisplatin and the Modulation of DNA Damage Response: New Ins

  2026-04-14

  Explore how Cisplatin (CDDP) not only drives apoptosis but also intersects with Wnt and EGFR pathways, reshaping the DNA damage response in cancer research. This article uncovers advanced mechanistic insights and protocol recommendations, offering a unique perspective beyond traditional cisplatin applications.

11276 records 1/752 page Next 12345 下5页 Last page